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Purpose: To compare the serum ferritin concentrations of normal pregnant women with those 
having gestational diabetes mellitus (GDM) and to determine the possible role of ferritin in 
predicting pregnancy outcome and early development of postpartum glucose intolerance and 
diabetes mellitus.
Method: This case-control study consisted of 128 pregnant women (64 women with GDM 
and 64 age-matched healthy pregnant women) seen at a university hospital in Zanjan, Iran. 
Anthropometric measurements were determined, and serum ferritin, C-reactive protein, insulin, 
glycosylated hemoglobin (HbA1c), and hemoglobin levels were measured. Pregnancy outcomes 
were recorded in all subjects. In the women with GDM, a diagnostic oral glucose tolerance test 
was performed eight weeks after delivery.
Results: Women with GDM had a higher concentration of serum ferritin (112 ± 28.4 pmol/L 
in GDM versus 65 ± 16.9 pmol/L in controls, P , 0.001). A positive correlation was found 
between serum ferritin level and mid-pregnancy fasting plasma glucose and HbAlc levels. 
Although women in the highest quartile of serum ferritin had a greater than two-fold increased 
risk of GDM, no significant correlation was found between ferritin levels and early postpartum 
oral glucose tolerance test results.
Conclusions: Elevated serum ferritin concentrations in mid-pregnancy are associated with an 
increased risk of GDM independent of C-reactive protein and body mass index. Ferritin levels 
in GDM cannot be used as an indicator to predict subsequent glucose concentration in early 
postpartum oral glucose tolerance test.
Keywords: gestational diabetes mellitus, ferritin, pregnancy outcome, diabetes mellitus, 
C-reactive protein
Introduction
Recent studies have reported positive associations of serum ferritin concentrations 
with cardiovascular risk factors,1 risk of insulin resistance syndrome, and risk of type 2 
diabetes.2–4 In our previous study in Iran, we showed elevated serum ferritin concentra-
tions in subjects with impaired glucose tolerance, known as a prediabetic state.5
Like impaired glucose tolerance in a nonpregnant subject, gestational diabetes 
mellitus (GDM) is an indicator for subsequent development of diabetes mellitus (DM) 
after delivery.6 Women with GDM are characterized by a relatively diminished insulin 
secretion coupled with pregnancy-induced insulin resistance.7 Causes of insulin resis-
tance are not completely understood; however high maternal weight is associated with Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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insulin resistance during pregnancy. Insulin resistance may be 
due to increasing secretion of human placental lactogen and 
other placental secretions or to a systemic inflammation dur-
ing pregnancy.8,9 There is an increasing recognition that iron 
overload may play a role in insulin resistance at the cellular 
level.10,11 Some epidemiologic studies have reported higher 
levels of ferritin in women with GDM.12,13 However, data are 
conflicting regarding whether elevated serum ferritin reflects 
inflammation or increased iron stores.14,15 Furthermore, data 
are not available on the relationship between serum ferritin 
concentrations during pregnancy and insulin resistance, 
and also the risk of subsequent development of postpartum 
impaired glucose tolerance and overt DM. The objective of 
this case-control study was to analyze serum ferritin and 
C-reactive protein concentrations in GDM and also to evaluate 
the association of ferritin with pregnancy outcomes and early 
development of postpartum glucose intolerance and DM.
Materials and methods
This case-control study was conducted at Vali-e-asr Hospital, 
a general hospital in Zanjan, a major city located to the west 
of Tehran and the capital of the Iranian province with the 
same name. The province has a predominantly urban popula-
tion of 1.1 million.
A total of 128 pregnant women, including 64 subjects with 
GDM and 64 healthy age-matched pregnant women, were 
enrolled serially at 24–28 weeks of gestation. All women with 
acute or chronic inflammatory or infective diseases,   history 
of malignancy, DM, seizure disorders, acute or chronic 
liver disease, acute or chronic renal disease, drug or alcohol 
abuse, and iron deficiency anemia were excluded. Perinatal 
iron supplementation was continued by all the participants 
based on a national policy, and all women received an equal 
dosage (50 mg of elemental iron per day) after the fourth 
month of pregnancy.
Prepregnant weight was used to calculate body mass index 
(BMI, weight in kilograms divided by the square of height in 
meters). Blood pressure was measured with the subject seated 
using a random zero sphygmomanometer. Blood pressure 
was measured twice on the left upper arm, and the average 
of the two measurements was used for analysis.
A two-step approach was applied to diagnose GDM. All 
the women were initially screened by the glucose challenge 
test with 50 g glucose at 24–28 weeks of gestation. A three-
hour oral glucose tolerance test was performed for women 
with plasma glucose concentrations exceeding 130 mg/
dL on a glucose challenge test. Carpenter/Coustan diag-
nostic criteria were used to interpret oral glucose   tolerance 
test results.16 The fasting plasma glucose concentration of 
the diagnosing oral glucose tolerance test was used as the 
mid-pregnancy fasting plasma glucose in this study.
Blood samples of the participants were collected at 
24–28 weeks of pregnancy after at least 12 hours of fast-
ing. Plasma glucose was measured by the glucose peroxi-
dase colorimetric enzymatic method, with a sensitivity of 
5 mg/dL. Glycosylated hemoglobin (HbA1c) (normal range 
4.8%–6.2%) was measured by ion exchange chromatography 
with DS5. Complete blood count was performed for all the 
participants using a hematologic analyzer (Sysmex, KX-21, 
Toa Co, Japan). C-reactive protein was measured by a high-
sensitivity assay, with the use of the latex particle-enhanced 
immunoturbidimetric assay, with an analytical sensitivity 
of 0.175 mg/dL and an upper limit of normal of 5 mg/dL. 
Serum ferritin was measured by a [I125] coated-tube immu-
noradiometric assay (Kavoshyar Co, Tehran). The assay 
was performed in duplicate. The interassay coefficients of 
variation ranged from 2% to 4%. Electrochemiluminescence 
immunoassay was used to detect serum insulin concentrations 
(Elecsys kit, Roche Diagnostics, Germany). The sensitivity 
of the assay was 1.3 pmol/L.
All the participants were followed until delivery, and their 
pregnancy outcomes were recorded. All subjects with rupture 
of membranes prior to 37 weeks’ gestation were considered to 
have preterm premature rupture of membranes. Preterm labor 
was defined as the presence of uterine contractions of sufficient 
frequency and intensity to affect progressive effacement and dila-
tion of the cervix prior to term gestation (20–37 weeks).   Dystocia 
was considered in subjects with difficult parturition to the point 
of needing human intervention due to large fetal size.
In women with GDM an additional two-hour oral glucose 
tolerance test with 75 g of glucose was performed eight weeks 
after delivery. The oral glucose tolerance test results were 
interpreted based on World Health Organization criteria.
Approval was obtained from the ethics committee of 
Zanjan University of Medical Sciences. All the participants 
were notified about the goals of the study, and informed 
consent was obtained.
Statistical analysis
Data are presented as mean ± standard deviation. Proportions 
were compared using the Chi-square test. Group means were 
compared using the Student’s t-test and analysis of variance 
(ANOVA). The Mann-Whitney test was used for variables with-
out a normal distribution. We also used log transformation for the 
variables without normal distribution, like ferritin and C-reactive 
protein. The Pearson correlation statistic was used to examine Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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the relationship between elevated serum ferritin and BMI. An 
odds ratio (OR) was calculated to compare the risk of GDM 
in people with higher ferritin levels. The conditional logistic 
regression analyses were performed to determine the influence 
of elevated serum ferritin on the risk of GDM and pregnancy 
morbidities. For independent variables, a change of 10 mmHg in 
blood pressure, 1 mg/dL of C-reactive protein, 1 µIU/L of insu-
lin, more than the 95th percentile of serum ferritin for normal 
pregnant women, and changes in BMI were considered in the 
analysis. BMI was categorized as normal, overweight, and obese 
in the analysis. In addition, a stepwise multiple linear regression 
analysis was performed, with the two-hour blood glucose after 
glucose load acting as the dependent variable. A significance 
of P , 0.05 was used for all statistical tests.
Results
Ferritin and risk of gDM
The baseline characteristics of participants with and without 
GDM are shown in Table 1. Serum ferritin concentration 
Table 1 Baseline clinical characteristics, biochemical indices, gDM risk factors and pregnancy complications of pregnant women with 
gDM and their control group (n = 128)
Variables (mean ± SD) GDM subjects (n = 64) Control subjects (n = 64) P value
Age (year) 30 ± 4.7 30 ± 4.9 0.8
Weight (kg) 75 ± 8 67.6 ± 9.9 0.00
BMi (kg/m2) 30.2 ± 3.2 27 ± 3.9 0.06
Systolic BP (mmhg) 111.7 ± 16 106.7 ± 11.9 0.06
Diastolic BP (mmhg) 72.8 ± 11.4 67.7 ± 9.1 0.01
gravidity 2.8 ± 1 2.5 ± 0.9 0.9
Parity 1.2 ± 0.6 1.3 ± 0.8 0.4
hb (g/dL)* 128 ± 8 125 ± 5.8 0.9
Ferritin (pmol/L)* 112.3 ± 28.4 65 ± 16.9 0.001
crP (mg/L)* 9.2 ± 1.7 7.3 ± 0.6 0.09
FPg (mmol/L)* 5.8 ± 0.18 4 ± 0.27 0.01
insulin (pmol/L)* 201 ± 111 347 ± 166 0.01
GDM risk factors (freq)
history of abortion 9 (14.1%) 4 (6.2%) 0.1
history of stillbirth 5 (7.8%) 1 (1.5%) 0.1
history of prior gDM 5 (7.8%) 0 (0%) 0.03
Family history of DM 30 (47%) 3 (4.6%) 0.001
Pregnancy morbidities (freq)
Pre-eclampsia and eclampsia  4 (6.7%) 0 0.1
hypertension  10 (16.7%) 0 0.001
PPrOM  2 (3.1%) 2 (3.1%) 0.6
Premature labor  5 (7.8%) 1 (1.5%) 0.1
Dystocia  3 (4.6%) 0 0.2
Abortion 1 (1.6) 0 0.3
LgA 13 (20.3) 0 0.00
LBW 0 0 1
cesarean section 45 (70.3%) 15 (23.4%) 0.00
Note: *All the measurements were performed at 24–28 weeks of pregnancy. 
Abbreviations: BMi, body mass index; BP, blood pressure; hb, hemoglobin; FPg, fasting plasma glucose; gDM, gestational diabetes mellitus; DM, diabetes mellitus; 
PPrOM, preterm premature rupture of membrane; LgA, large for gestational age; crP, c-reactive protein; freq, frequency; LBW, low birth weight.
was significantly higher in pregnant women with GDM. 
Hemoglobin levels were not significantly different between 
the two groups. Linear relationships between serum ferritin 
with mid-pregnancy fasting plasma glucose (r = 0.241, 
P = 0.01) and HbA1c were observed. A negative correlation 
between serum ferritin and fasting serum insulin concentra-
tion was also determined (r = −0.332, P = 0.02). There was no 
significant correlation between serum ferritin and C-reactive 
protein levels.
A ferritin concentration of 84.7 pmol/L was calculated 
to be the 75th percentile for healthy pregnant women. 
Considering this level as the cutoff point to define high ferritin 
levels, 26 patients (65%) in the GDM group and 14 normal 
subjects (21.8%) exhibited high ferritin levels (P = 0.02). 
The risk of having GDM with these high levels of ferritin 
was calculated to be 2.3-fold higher than that for patients 
with lower ferritin concentrations (OR 2.3, 95% confidence 
interval [CI] 1.06–5.1). For women with a ferritin level above 
186 pmol/L (95th percentile for healthy pregnant women), Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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the risk of having GDM was calculated to be 4.4-fold higher 
than the risk for those with lower concentrations of ferritin 
(OR 4.4, 95% CI 1.19–16.8). This risk estimation remained 
significantly positive but was moderately reduced after adjust-
ment for C-reactive protein and other confounding variables 
like BMI, blood pressure, history of GDM, and family history 
of DM (OR 2.4, 95% CI 1.2–6.8).
Logistic regression analyses were performed to determine 
the influence of elevated serum ferritin on the risk of GDM. 
Potential confounding variables, including age, familial history 
of DM, BMI, blood pressure, C-reactive protein, and insulin 
concentrations were included in multivariable models. The 
most potent prognostic variables in this model were family 
history of DM and serum ferritin concentrations (Table 2).
gDM risk factors  
and pregnancy complications
Table 1 compares GDM cases with normal pregnant women 
for the frequency of some risk factors and pregnancy compli-
cations. Obesity was more prevalent in the cases with GDM 
(22 subjects [39%] in the GDM group versus nine subjects 
[14%] in the control group, P = 0.002). Positive family history 
for DM, especially paternal history of DM, was significantly 
more prevalent in the GDM patients (31% of paternal DM 
versus 8% of history of maternal DM, P = 0.001).
A logistic regression analysis was used to determine 
the influence of elevated serum ferritin on the risk of 
pregnancy morbidities, including pre-eclampsia, preterm 
premature rupture of membranes, dystocia, and premature 
labor. Confounding variables including age, BMI, blood 
pressure, fasting plasma glucose, HbA1c, C-reactive protein, 
and insulin concentrations were included in the model. The 
only significant prognostic variable in this model was mid-
pregnancy fasting plasma glucose concentrations (OR 3.1, 
95% CI 1.9–18).
Ferritin and early postpartum  
glucose tolerance
All the GDM subjects were evaluated eight weeks after 
delivery. Based on a standard oral glucose tolerance test 
with 75 g glucose, DM and impaired glucose tolerance 
were diagnosed in eight (12.5%) and 15 subjects (23.4%), 
respectively. A comparison between GDM patients who 
developed impaired glucose tolerance or DM and those 
who presented with a normal postpartum oral glucose 
tolerance test in terms of general characteristics, basal 
laboratory data, and pregnancy complications appears in 
Table 3. Although a significant difference was found in 
mid-pregnancy blood pressure and fasting plasma glu-
cose between the two groups, no difference was found for 
blood glucose levels at hours 1, 2, or 3 after oral glucose 
loading at the time of diagnosis of GDM. Furthermore, 
the frequency of pregnancy complications was similar in 
both groups.
Stepwise linear regression analyses were performed to 
determine the relationship between elevated serum ferritin 
and two-hour plasma glucose in the postpartum oral glucose 
tolerance test. The postpartum two-hour plasma glucose 
concentration after a standard oral glucose tolerance test was 
considered to be the dependent variable. Potential confound-
ing variables, including history of prior GDM, family history 
of DM, BMI, blood pressure, mid-pregnancy fasting plasma 
glucose, plasma glucose concentration at the first, second, and 
third hour after 100 g oral glucose load, C-reactive protein, 
and insulin concentration, were included in the model. There 
was no significant relationship between ferritin and two-hour 
plasma glucose concentration in the postpartum oral glucose 
tolerance test. We determined that only mid-pregnancy fast-
ing plasma glucose (OR 1.05, 95% CI 1.01–1.1) and BMI 
(OR 1.4, 95% CI 1.2–4.7) were prognostic for postpartum 
two-hour plasma glucose concentration in the oral glucose 
tolerance test. Although a correlation between positive 
family history of DM and presence of hypertension during 
Table  2  Logistic  regression  analyses  of  ferritin  and  other 
confounding variables to predict gDM in the pregnant women
Dependent variable Independent variables OR CI (95%)
Model 1
gDM  Ferritin 4.4 1.2–16.8
Family history of DM 11.5 3–43.3
BMi 2.6 1.2–5.4
Age 0.98 0.9–1.07
Model 2
gDM Ferritin 5.8 1–38
Family history of DM 11.3 2.7–46
BMi 2.9 1.2–7.1
Age 0.98 0.89–1.08
Systolic BP 0.69 0.3–1.2
Diastolic BP 2.3 1.1–4.9
Model 3
gDM Ferritin 5.1 1–34
Family history of DM 11.2 2.6–45
BMi 2.8 1.2–4.9
Age 0.97 0.89–1.05
Systolic BP 0.7 0.35–1.3
Diastolic BP 2.4 1.1–5.1
crP 0.91 0.7–1.09
Abbreviations:  gDM,  gestational  diabetes  mellitus;  DM,  diabetes  mellitus; 
BMi, body mass index; BP, blood pressure; crP, c-reactive protein; Or, odds ratio; 
ci, confidence interval.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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Table 3 comparison of basal clinical characteristics, biochemical indices, past history, and pregnancy complications between two 
groups of women with gDM based on their postpartum OgTT results (n = 64)
Variables (mean ± SD) Impaired glucose tolerance or DM (n = 23) Normal glucose tolerance (n = 41) P
Age (years) 30.3 ± 1.1 30.4 ± 0.7 0.9
BMi (kg/m2) 31.3 ± 0.5 29.6 ± 0.5 0.06
Systolic BP (mmhg) 118 ± 40 107.7 ± 21 0.01
Diastolic BP (mmhg) 77 ± 25 70 ± 17 0.03
hb (g/dL) 129 ± 2.3 128 ± 1.8 0.8
Ferritin (pmol/L) 107.8 ± 22 115.9 ± 24.7 0.8
crP (mg/L) 9.5 ± 1.5 8.9 ± 1.9 0.09
FPg (mmol/L) 6.1 ± 0.2 5 ± 0.17 0.00
insulin (pmol/L) 234 ± 122 182 ± 99 0.06
1-hour BS in gTT (mmol/L) 10.8 ± 0.76 9.6 ± 0.3 0.08
2-hour BS in gTT (mmol/L) 10.8 ± 0.85 9.8 ± 0.58 0.3
3-hour BS in gTT (mmol/L) 9.4 ± 1.2 7.8 ± 0.3 0.3
hbA1c (%) 5.16 ± 0.19 5.1 ± 0.16 0.8
GDM risk factors (freq)
history of abortion 4 (17.3) 5 (12) 0.9
history of stillbirth 2 (8.7) 3 (7.3) 0.6
history of prior gDM 4 (17.3) 1 (2.4) 0.06
Family history of DM 16 (69.5) 14 (34) 0.08
Pregnancy morbidity (freq)
Pre-eclampsia and eclampsia 4 (17.3) 0 0.06
hypertension 4 (17.3) 2 (4.8) 0.1
PPrOM  1 (4.3) 1 (2.4) 0.6
Premature labor 3 (13) 2 (4.8) 0.2
Dystocia 3 (13) 0 0.052
LgA 8 (34.7) 6 (14.6) 0.04
cesarean section 18 (78.3) 27 (65.9) 0.2
Abbreviations: BMi, body mass index; BP, blood pressure; hb, hemoglobin; FPg, fasting plasma glucose; crP, c-reactive protein; 1-hour BS, blood sugar one hour 
post-OgTT in mid-pregnancy; 2-hour BS, blood sugar two hours post-OgTT; 3-hour BS, blood sugar three hours post-OgTT; OgTT, oral glucose tolerance test; 
gDM, gestational diabetes mellitus; DM, diabetes mellitus; PPrOM, preterm premature rupture of membrane; LgA, large for gestational age.
pregnancy with postpartum two-hour glucose concentration 
was observed, this correlation was modified and lost signifi-
cance after adjusting for BMI.
Discussion
We found a significant association between serum ferritin 
levels and GDM that was independent of BMI and C-reactive 
protein. However, no association of serum ferritin levels with 
pregnancy morbidities or postpartum glucose concentration 
in the oral glucose tolerance test was found.
Other studies has revealed that higher ferritin levels raise 
the risk of DM3,4 and prediabetic conditions.5 Whether this 
association is independent of BMI is not clear.1,2,14,17 Few 
data regarding the correlation of ferritin levels and body fat 
during pregnancy have been reported. In spite of reports from 
China that revealed no correlation between ferritin levels and 
BMI in pregnant Chinese women,11 a report from the US 
demonstrated a significant correlation.12 In the current study, 
ferritin level was an independent prognostic factor for GDM 
and was highly correlated with glycemic control.
Women with GDM are characterized by relatively 
diminished insulin secretion, coupled with pregnancy-
induced insulin resistance, primarily in skeletal muscle 
tissue.7 In the current study, it is interesting that the fasting 
serum insulin concentration was significantly lower in the 
GDM group than that in the non-GDM group (201 ± 111 
versus 347 ± 166 pmol/L). Although a lower insulin level 
was not an independent risk factor for developing GDM in 
this study, this finding implies that insulin secretion might 
be decreased in the GDM group. There have been similar 
reports stating that β-cell function is decreased in patients 
with GDM.18,19
It is not clear how ferritin is related to insulin deficiency or 
to insulin resistance. Ferritin has been identified as a marker 
of inflammation, and pregnancy is considered an inflamma-
tory state. Whether or not elevated serum ferritin in GDM 
is a consequence of inflammation is not clear. Although it 
would be of interest to assess levels of ferritin at different time 
points of pregnancy, we could not do that because of difficult 
accessing the same subjects on several occasions. However, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2010:3 submit your manuscript | www.dovepress.com
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with the case-control design used in our study, the effect of 
the inflammatory state of pregnancy on ferritin levels has been 
removed. Similar to a previous study,12 we did not find a posi-
tive correlation between C-reactive protein (an inflammation 
marker) and ferritin. On the other hand, although the role of 
ferritin as a potent indicator of GDM was confirmed in this 
study, C-reactive protein was not able to be determined to be 
an independent risk factor for development of GDM.
Jiang et al20 found that high serum ferritin and C-reactive 
protein levels are independent risk factors for type 2 diabetes. 
These data are inconsistent with the role of inflammation 
in raising ferritin levels in GDM and other insulin-resistant 
states.
Ferritin can reflect body iron stores. Higher iron stores 
can be associated with insulin resistance in nonpregnant 
subjects.17,20 Lao et al found that higher hemoglobin 
(.13 g/dL) was an independent risk for GDM21 and that iron 
deficiency anemia is associated with a lower risk of GDM.22 
Like a previous report,12 our results revealed no correlation 
between ferritin and hemoglobin concentrations. Further-
more, no difference in hemoglobin concentrations was found 
between women with GDM and the control group. Although 
these findings do not support the hypothesis that higher 
serum ferritin levels reflect excess iron stores in patients 
with GDM, we cannot rule out subclinical manifestations of 
iron overload in GDM. One limitation of our study is that we 
did not measure serum iron or serum transferrin concentra-
tions, which would have helped us to interpret the role of 
serum ferritin as a marker of iron overload during pregnancy. 
Minimal iron excess that does not have a significant effect 
on the hemoglobin concentration may affect insulin action 
or insulin secretion at the cellular level.2 Recently, a genetic 
susceptibility to iron overload in GDM was suggested.23
GDM was a potent risk factor for subsequent development 
of DM, increasing the risk of DM by 12.5%. Mid-pregnancy 
fasting plasma glucose (and not postoral glucose tolerance test 
blood sugars) and BMI were the strongest prognostic factors 
for early postpartum impaired glucose tolerance or DM. Ferri-
tin was not correlated with blood glucose levels after delivery. 
Lack of a correlation between ferritin and postpartum glucose 
tolerance test results may be due to the relatively small sample 
size. On the other hand, an oral   glucose tolerance test was per-
formed eight weeks after delivery, which may have been too 
early to find an association between ferritin level and glucose 
intolerance. Furthermore, a family history of DM and history 
of prior GDM were proven not to be independent predictors of 
postpartum DM. Although these data are consistent with those 
reported by Huidobro,24 there are reports of high postpartum 
oral glucose tolerance test plasma glucose levels that predict 
future DM.25,26 We could not find any study on ferritin as a 
risk factor for postpartum diabetes. This is the first report 
in this field that demonstrates the lack of any relationship 
between ferritin levels at the time of diagnosis of GDM and 
early postpartum oral glucose tolerance test results.
In conclusion, we found that the serum ferritin level is 
highly associated with GDM independently of BMI and 
C-reactive protein, the mid-pregnancy ferritin level is not 
a prognostic factor for pregnancy morbidity or subsequent 
impaired glucose tolerance after delivery, and fasting plasma 
glucose values at the time of diagnosis of GDM are the most 
important prognostic factors for glucose concentration in an 
early postpartum oral glucose tolerance test.
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